Study guide
14.2 Distribution & Protein Binding
DHA Pharmacist Licensing Assessment PHO5481
Track your progress as you read
Finished sections get a check mark.
1 Exam Overview & Licensing Pathway
1.1 Current Exam Facts & Format 1.2 Eligibility, PQR & the Sheryan Application Process 1.3 Study Strategy & Test-Day Plan
2 Cardiovascular Pharmacology
2.1 Antihypertensives & RAAS Agents 2.2 Heart Failure & Antiarrhythmic Drugs 2.3 Lipid-Lowering & Antianginal Agents
3 Endocrine & Metabolic Pharmacology
3.1 Insulin & Oral Antidiabetic Agents 3.2 Thyroid, Bone & Calcium Agents 3.3 Corticosteroids & Other Hormonal Agents
4 Anti-Infective Pharmacology
4.1 Beta-Lactam Antibiotics 4.2 Non-Beta-Lactam Antibacterials 4.3 Antifungals, Antivirals & Antituberculars
5 CNS, Psychiatric & Pain Pharmacology
5.1 Psychiatric Pharmacology 5.2 Antiepileptics & Neurologic Agents 5.3 Analgesics: NSAIDs, Opioids & Migraine
6 Respiratory, GI & Hematology Pharmacology
6.1 Respiratory Pharmacology 6.2 Gastrointestinal Pharmacology 6.3 Anticoagulants, Antiplatelets & Hematology Agents
7 Pharmaceutical Care: Cardiometabolic Disease
7.1 Diabetes Management & Counseling 7.2 Hypertension & Dyslipidemia Management 7.3 Heart Failure & Anticoagulation Management
8 Pharmaceutical Care: Respiratory, Rheumatology & Infection
8.1 Asthma & COPD Management 8.2 Gout, Pain & Rheumatologic Care 8.3 Infection Management & Antimicrobial Stewardship
9 Counseling, Monitoring & Special Populations
9.1 Patient Counseling, Adherence & Health Literacy 9.2 Therapeutic Monitoring & Laboratory Interpretation 9.3 Pregnancy, Pediatrics, Geriatrics & Organ Impairment 9.4 Pharmacoeconomics & Formulary Decision Making
10 Pharmaceutical Calculations I
10.1 Concentration, Ratio & Percentage Strength 10.2 Weight-Based & BSA Dosing 10.3 Dilution, Concentration & Alligation
11 Pharmaceutical Calculations II
11.1 Infusion Rates & IV Flow Calculations 11.2 Dispensing Quantities & Days' Supply 11.3 Compounding Calculations, Isotonicity & Milliequivalents
12 UAE Pharmacy Law & Regulation
12.1 UAE Regulatory Framework & Licensing Authorities 12.2 Medicine Registration, Pricing & Supply Chain 12.3 Prescription Requirements & Validity
13 Controlled Drugs, Ethics & Pharmacovigilance
13.1 Controlled & Semi-Controlled Medicines in the UAE 13.2 Ethics, Confidentiality & Generic Substitution 13.3 Pharmacovigilance, Recall & Medicine Disposal
14 Pharmacokinetics I: ADME
14.1 Absorption & Bioavailability 14.2 Distribution & Protein Binding 14.3 Metabolism & Elimination
15 Pharmacokinetics II: Kinetics, Dosing & TDM
15.1 Half-Life, Clearance & Kinetic Order 15.2 Loading & Maintenance Dosing 15.3 Therapeutic Drug Monitoring
16 OTC Medicines & Self-Care
16.1 Cough, Cold & Allergic Rhinitis 16.2 GI Self-Care: Heartburn, Constipation & Diarrhoea 16.3 Pain & Fever Self-Care 16.4 Referral Red Flags, Emergency Contraception & Skin
17 Medication Safety
17.1 High-Alert Medications & Error-Prone Abbreviations 17.2 Medication Reconciliation & Duplicate Therapy 17.3 Adverse Drug Reactions & Hypersensitivity Recognition
18 Sterile & Nonsterile Compounding
18.1 Aseptic Technique & Compounding Environments 18.2 Parenteral, TPN & Cytotoxic Preparation 18.3 Nonsterile Compounding
19 Pharmaceutics, Biopharmaceutics & Toxicology
19.1 Dosage Form Design & the Biopharmaceutics Classification System 19.2 Dissolution & Excipients 19.3 Toxicology: Poisoning Recognition & Antidotes
20 Infection Control, Natural Products, Medicinal Chemistry & Pharmacogenomics
20.1 Infection Control & Immunization 20.2 Pharmacognosy & Dietary Supplements 20.3 Medicinal Chemistry Essentials 20.4 Clinical Pharmacogenomics
14.2 Distribution & Protein Binding
Key Takeaways Explain This Topic AI
Vd = Dose ÷ Cp₀ after an IV bolus; it is an apparent volume — compare it with plasma (~0.07 L/kg), ECF (~0.2 L/kg) and total body water (~0.6 L/kg)
Warfarin (Vd ~0.1 L/kg) stays in plasma; digoxin (~7 L/kg) binds skeletal/cardiac muscle; chloroquine (~200 L/kg) is massively tissue-sequestered — large-Vd drugs are not dialysable in overdose
Only unbound drug is active, distributes, is metabolized and is filtered: albumin binds acidic drugs (warfarin, phenytoin), alpha-1 acid glycoprotein binds basic drugs (lidocaine, propranolol)
Displacement interactions matter only for drugs that are >90% bound, with small Vd and a narrow therapeutic index — and even then the free-drug rise is usually transient
- Loading dose = Vd × target Cp ÷ F; it depends on Vd, not clearance (clearance sets the maintenance dose)
- Last updated: August 2026
Volume of Distribution
After IV injection, drug distributes between plasma and tissues. The (apparent) volume of distribution (Vd) relates the amount of drug in the body to the measured plasma concentration:
Vd = Amount of drug in body ÷ Plasma concentration = Dose ÷ Cp₀ (for an IV bolus, where Cp₀ is the extrapolated concentration at time zero)
Worked example: A 500 mg IV bolus produces an extrapolated Cp₀ of 20 mg/L.
Vd = 500 mg ÷ 20 mg/L = 25 L
Vd is apparent , not anatomical — it is the volume that would be required to contain the total body drug at the measured plasma concentration. It is best expressed per kilogram (L/kg) and compared with body water compartments: plasma ≈ 0.07 L/kg, extracellular fluid ≈ 0.2 L/kg, total body water ≈ 0.6 L/kg.
Interpreting small versus large Vd
- Drug Approx. Vd (L/kg) Interpretation
- Warfarin ~0.1 Highly plasma-protein bound; confined mainly to plasma and extracellular fluid
- Phenytoin ~0.6–0.7 Distributes into roughly total body water
- Digoxin ~7 Extensive binding to skeletal and cardiac muscle Na⁺/K⁺-ATPase
- Chloroquine ~200 Massive tissue sequestration; most of the drug is outside plasma
Rules of thumb:
Small Vd (<0.3 L/kg) : hydrophilic or highly protein-bound drug; plasma levels respond strongly to dose changes; more readily removed by dialysis.
Large Vd (>1 L/kg) : lipophilic or extensively tissue-bound drug; dialysis is ineffective in overdose; loading doses must be large.
Physiological determinants of Vd
Lipophilicity — lipophilic drugs leave plasma and enter fat and tissue (large Vd).
Tissue binding — e.g., digoxin to muscle Na⁺/K⁺-ATPase; tetracyclines to growing bone and teeth.
Plasma protein binding — extensive binding retains drug in plasma (small Vd).
Patient factors — age, sex and body composition (elderly patients have less body water, so hydrophilic drugs such as digoxin reach higher concentrations); oedema and ascites increase the Vd of hydrophilic drugs.
One-Compartment versus Two-Compartment Models
In a one-compartment model the body behaves as a single, instantly mixing tank: the log plasma concentration–time plot after an IV bolus is a straight line with a single elimination slope. In a two-compartment model , plasma concentration falls biexponentially :
a rapid distribution (alpha) phase as drug moves from plasma (central compartment) into well-perfused tissues, followed by
a slower elimination (beta) phase once pseudo-equilibrium is reached.
This matters clinically: with drugs such as digoxin, plasma sampled during the distribution phase is misleadingly high — draw levels at least 6 hours post-dose.
Plasma Protein Binding
In plasma, drugs exist in equilibrium between bound (inactive, non-diffusible) and free (unbound) fractions. Only the unbound drug can distribute, bind receptors, be metabolized and be filtered at the glomerulus.
Albumin binds mainly acidic drugs: warfarin (~99% bound), phenytoin (~90%), NSAIDs, sulfonamides, valproate.
Alpha-1 acid glycoprotein (AAG) binds mainly basic drugs: lidocaine, propranolol, imipramine, quinidine. AAG is an acute-phase reactant — it rises in inflammation and trauma, lowering the free fraction of basic drugs.
Displacement interactions
One highly bound drug can displace another from albumin, transiently raising the free, active fraction. The classic historical example is phenylbutazone displacing warfarin — a sharp rise in free warfarin with bleeding risk (phenylbutazone also inhibits warfarin metabolism, amplifying and prolonging the effect). Similarly, valproate displaces phenytoin and inhibits its metabolism, so total phenytoin may fall while free (active) phenytoin rises — monitor free levels, not just total.
Displacement interactions are clinically important only when all of the following hold:
- the displaced drug is >90% protein bound (a small displaced fraction is then relatively large),
- it has a small volume of distribution (displaced drug stays near plasma), and
it has a narrow therapeutic index (warfarin, phenytoin).
Even then, the rise in free drug is usually transient : more free drug is also more available for metabolism and excretion, so a new steady state is reached — unless clearance is simultaneously inhibited.
Hypoalbuminemia and the Phenytoin Correction
Low albumin — in nephrotic syndrome , liver failure, malnutrition, pregnancy , the elderly , burns and critical illness — increases the free fraction of highly bound acidic drugs. The total measured concentration then underestimates pharmacological activity. The trap drug is phenytoin : a 'low-normal' total level in a hypoalbuminemic patient may conceal a therapeutic or even toxic free level.
The Sheiner-Tozer equation estimates what the total phenytoin level would be at normal albumin:
- Adjusted total phenytoin = Measured total ÷ [(0.2 × albumin in g/dL) + 0.1]
- (Use 0.25 instead of 0.2 when renal function is severely impaired.)
Worked example: measured total phenytoin 8 mg/L, serum albumin 2.0 g/dL:
Denominator = (0.2 × 2.0) + 0.1 = 0.5
Adjusted level = 8 ÷ 0.5 = 16 mg/L — comfortably within the usual 10–20 mg/L target range, despite the apparently subtherapeutic raw result. Where available, a directly measured free (unbound) phenytoin (target 1–2 mg/L) is preferable.
Barriers to Distribution
Blood-brain barrier (BBB) : tight junctions between capillary endothelial cells plus P-glycoprotein efflux. Only small, lipophilic, unionized drugs cross readily — levodopa does, dopamine does not, hence levodopa (not dopamine) is used in Parkinson's disease. Meningeal inflammation partly disrupts the barrier, which is why penicillins achieve therapeutic CSF levels in bacterial meningitis.
Placenta : behaves like a lipid barrier — lipophilic, unionized drugs (including most general anaesthetics and opioids) cross freely; large polar molecules (e.g., heparin) do not. For most small molecules the placenta is a sieve, not a shield.
Loading Dose
To reach a therapeutic concentration immediately rather than waiting ~4–5 half-lives for accumulation:
Loading dose = (Vd × target plasma concentration) ÷ F
Worked example — digoxin (70 kg adult, target 1 µg/L, Vd ≈ 7 L/kg, IV so F = 1):
Vd = 7 × 70 = 490 L
Loading dose = 490 L × 1 µg/L = 490 µg ≈ 0.5 mg (in practice given in divided doses, and rounded to available strengths if oral, where F ≈ 0.7)
Note that the loading dose depends on Vd , not clearance — clearance governs the maintenance dose (Section 14.3).